Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.59 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.59 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.59 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL30104639 | 0.99 | SMN1; SMN2 (0.70) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL21688577 | 0.95 | CYP1A2 (0.65) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL19821581 | 0.95 | CYP1A2 (0.65) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL30104661 | 0.94 | CYP1A2 (0.64) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL18651503 | 0.94 | CYP1A2 (0.64) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL18651504 | 0.94 | CYP1A2 (0.64) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL20511593 | 0.93 | SMN1; SMN2 (0.71) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL20511607 | 0.93 | SMN1; SMN2 (0.71) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Maleic Acid SCHEMBL30104604 | 0.93 | SMN1; SMN2 (0.78) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Maleic Acid SCHEMBL28342898 | 0.93 | SMN1; SMN2 (0.78) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | ADRB2 669/4885ADRB1 561/4885HTR1A 2104/4885 |
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | ADRB2 669/4885ADRB1 561/4885HTR1A 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.